Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1978 Sep;188(3):372–376. doi: 10.1097/00000658-197809000-00012

Correlation of estrophilin content of primary mammary cancer to eventual endocrine treatment.

G E Block, R S Ellis, E DeSombre, E Jensen
PMCID: PMC1396970  PMID: 686899

Abstract

The estrogen receptor protein content of recurrent breast cancer correlates well with the clinical response of hormonal manipulation. This predictive value of the ER of the primary tumor obtained at the time of mastectomy has not yet been proven. If this predictive capability should hold for primary tumors and eventual endocrine treatment, the ramifications are obvious: endocrine therapy could be offered to patients on a rational basis and adjuvant therapy could be considered on a plausible biochemical basis. This report details our observations as to the ER content of the primary tumor and the eventual result of endocrine therapy. Thirty-seven patients whose tumor ER was determined from the primary tumor eventually underwent some form of endocrine therapy for recurrent disease. Fifteen of the primary tumors had significant ER content and 22 possessed insignificant amounts. Only one of the 22 patients with insignificant ER content was benefited by endocrine treatment. Those patients whose tumors contained low amounts of ER experienced recurrence of their disease more rapidly than did those with higher ER content. There was no correlation of age, cell type of tumor or metastatic site with the ER content of the tumor. There is a positive correlation between response to chemotherapy and ER content of tumor. Measurement of the estrogen receptor protein content of the primary breast tumor is a reliable method for choosing patients for eventual endocrine therapy. Those patients whose tumors contain insignificant estrophilin are not candidates for such attempts at palliation.

Full text

PDF
372

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Block G. E., Jensen E. V., Polley T. Z. The prediction of hormonal dependency of mammary cancer. Ann Surg. 1975 Sep;182(3):342–352. doi: 10.1097/00000658-197509000-00017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bonadonna G., Rossi A., Valagussa P., Banfi A., Veronesi U. The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance. Cancer. 1977 Jun;39(6 Suppl):2904–2915. doi: 10.1002/1097-0142(197706)39:6<2904::aid-cncr2820390677>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  3. FOLCA P. J., GLASCOCK R. F., IRVINE W. T. Studies with tritium-labelled hexoestrol in advanced breast cancer. Comparison of tissue accumulation of hexoestrol with response to bilateral adrenalectomy and oophorectomy. Lancet. 1961 Oct 7;2(7206):796–798. doi: 10.1016/s0140-6736(61)91088-1. [DOI] [PubMed] [Google Scholar]
  4. Fisher B., Carbone P., Economou S. G., Frelick R., Glass A., Lerner H., Redmond C., Zelen M., Band P., Katrych D. L. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med. 1975 Jan 16;292(3):117–122. doi: 10.1056/NEJM197501162920301. [DOI] [PubMed] [Google Scholar]
  5. Greene G. L., Closs L. E., Fleming H., DeSombre E. R., Jensen E. V. Antibodies to estrogen receptor: immunochemical similarity of estrophilin from various mammalian species. Proc Natl Acad Sci U S A. 1977 Sep;74(9):3681–3685. doi: 10.1073/pnas.74.9.3681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. HUGGINS C., DAO T. L-Y. Characteristics of adrenal-dependent mammary cancers. Ann Surg. 1954 Oct;140(4):497–501. doi: 10.1097/00000658-195410000-00005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Heuson J. C., Longeval E., Mattheiem W. H., Deboel M. C., Sylvester R. J., Leclercq G. Significance of quantitative assessment of estrogen receptors for endocrine therapy in advanced breast cancer. Cancer. 1977 May;39(5):1971–1977. doi: 10.1002/1097-0142(197705)39:5<1971::aid-cncr2820390510>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  8. Jensen E. V., Smith S., DeSombre E. R. Hormone dependency in breast cancer. J Steroid Biochem. 1976 Nov-Dec;7(11-12):911–917. doi: 10.1016/0022-4731(76)90010-8. [DOI] [PubMed] [Google Scholar]
  9. King R. J. Clinical relevance of steroid-receptor measurements in tumours. Cancer Treat Rev. 1975 Dec;2(4):273–293. doi: 10.1016/s0305-7372(75)80009-0. [DOI] [PubMed] [Google Scholar]
  10. McGuire W. L. Current status of estrogen receptors in human breast cancer. Cancer. 1975 Aug;36(2):638–644. doi: 10.1002/1097-0142(197508)36:2+<638::aid-cncr2820360805>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  11. Rosen P. P., Menendez-Botet C. J., Nisselbaum J. S., Urban J. A., Miké V., Fracchia A., Schwartz M. K. Pathological review of breast lesions analyzed for estrogen receptor protein. Cancer Res. 1975 Nov;35(11 Pt 1):3187–3194. [PubMed] [Google Scholar]
  12. Wittliff J. L., Beatty B. W., Savlov E. D., Patterson W. B., Cooper R. A., Jr Estrogen receptors and hormone dependency in human breast cancer. Recent Results Cancer Res. 1976;(57):59–77. doi: 10.1007/978-3-642-81043-5_7. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES